Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate

Journal of Bone and Mineral Research

Volumn 16, Issue 10, 2001, Pages 1739-1746

  Stroup, George B ^a   Lark, Michael W ^a   Veber, Daniel F ^a   Bhattacharyya, Amit ^a   Blake, Simon ^a   Dare, Lauren C ^a   Erhard, Karl F ^a   Hoffman, Sandra J ^a   James, Ian E ^a   Marquis, Robert W ^a   Ru, Yu ^a   Vasko Moser, Janice A ^a   Smith, Brian R ^a   Tomaszek, Thadeus ^a   Gowen, Maxine ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Antiresorptive; Cathepsin K; Cysteine protease; Macaca fascicularis; Primate

Indexed keywords

BIOCHEMICAL MARKER; CATHEPSIN K; CYSTEINE PROTEINASE INHIBITOR; LEUPRORELIN; OSTEOCALCIN; PEPTIDE DERIVATIVE; SB 357114; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE ATROPHY; BONE TURNOVER; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MACACA; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS;

EID: 0034808707     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2001.16.10.1739     Document Type: Article

References (33)

1. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts
2. Cathepsin K: Isolation and characterization of the murine cDNA and genomic sequence, the homologue of the human pycnodysostosis gene
3. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency
4. A nonsense mutation in the cathepsin K gene observed in a family with pycnodysostosis
5. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization
6. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice
7. Mechanism of inhibition of cathepsin K by potent, selective 1,5-diacylcarbohydrazides: A new class of mechanism-based inhibitors of thiol proteases
8. Peptide aldehyde inhibitors of cathepsin k inhibit bone resorption both in vitro and in vivo
9. Potent dipeptidylketone inhibitors of the cysteine protease cathepsin K
10. Conformationally constrained 1,3-diamino ketones - A series of potent inhibitors of the cysteine protease cathepsin K
11. Cathepsin k antisense oligodeoxynucleotide inhibits osteoclastic bone resorption
12. Cynomolgus monkey (Macaca fascicularis) cathepsin K: Cloning, expression, purification, and activation
13. Changes in bone turnover following gonadotropin-releasing hormone (GnRH) agonist administration and estrogen treatment in cynomolgus monkeys: A short-term model for evaluation of antiresorptive therapy
14. Cyclic ketone inhibitors of the cysteine protease cathepsin K
15. Statistical analysis of enzyme kinetic data
16. Human osteoclast cathepsin K is processed intracellularly prior to attachment and bone resorption
17. Human osteoclastoma-derived stromal cells: Correlation of the ability to form mineralized nodules in vitro with formation of bone in vivo
18. Development and characterization of a human in vitro resorption assay: Demonstration of utility using novel antiresorptive agents
19. Quantification of the collagenolytic activity of isolated osteoclasts by enzyme-linked immunosorbent assay
20. Application of a new serum assay for type i collagen cross-linked n-telopeptides - Assessment of diurnal changes in bone turnover with and without alendronate treatment
21. Proteolysis of human bone collagen by cathepsin K: Characterization of the cleavage sites generating the cross-linked N-telopeptide neoepitope
22. The collagenolytic activity of cathepsin K is unique among mammalian proteinases
23. Human cathepsin K cleaves native type i and ii collagens at the n-terminal end of the triple helix
24. Cysteine proteinases and matrix metalloproteinases play distinct roles in the subosteoclastic resorption zone
25. Potent and selective cathepsin L inhibitors do not inhibit human osteoclast resorption in vitro
26. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: A randomized, controlled clinical trial
27. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation
28. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women
29. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women - A randomized clinical trial
30. Treatment of osteoporoses by manipulation of coherent bone cell populations
31. Coherence therapy does not prevent axial bone loss in osteoporotic women: A preliminary comparative study
32. The effects of etidronate on trabecular bone remodeling in postmenopausal spinal osteoporosis: A randomized study comparing intermittent treatment and an ADFR regime